Johnson & Johnson (JNJ) Financials, Dividends & Stock Info
Explore comprehensive financial data for Johnson & Johnson, provided completely free. Analyze revenue, net income, profit margins, dividend history, and key financial ratios to make informed investment decisions.
Data as of (571 days ago)|Source: SEC EDGAR
The information on this page is for informational purposes only and does not constitute investment advice, financial advice, or any recommendation. Billiver does not recommend buying, selling, or holding any security. Past performance is not indicative of future results.
Data may be delayed and accuracy is not guaranteed. All investment decisions are solely your responsibility. Verify information independently and consult a qualified financial advisor before investing. About · Methodology
Johnson & Johnson (JNJ) is a pharmaceuticals company. The company reports annual revenue of $92.1B and net income of $25.1B. Its profit margin is 27.3%.
Johnson & Johnson Key Financials(TTM Est.)
Data from SEC EDGAR filings. TTM = Trailing Twelve Months.
Johnson & Johnson Financial Health ScoreFY2025
Good overall health with some areas for improvement
0 pts YoYThis Financial Health Score is a proprietary metric calculated from SEC EDGAR filings for educational and informational purposes only. It does not constitute investment advice or a recommendation to buy or sell any security. Results vary significantly by industry. Conduct your own research before making investment decisions.
Data Highlights
- Strong profit margin: 27.3%
- Strong return on equity: 31.7%
Data sourced from SEC EDGAR filings. Not investment advice.
Johnson & Johnson Recent Events
Source: SEC EDGAR 8-K Filings
5-Year Revenue & Net Income Trend
Chart shows fiscal year data from SEC EDGAR filings. Hover over data points for details.
As of FY2025 · SEC 10-K · Updated Mar 11, 2026
Revenue Breakdown (FY2024)
See Johnson & Johnson detailed breakdown →Showing top 3 of 37 segments
About Johnson & Johnson
Johnson & Johnson (J&J) is an American multinational pharmaceutical, biotechnology, and medical technologies corporation headquartered in New Brunswick, New Jersey, and publicly traded on the New York Stock Exchange. Its common stock is a component of the Dow Jones Industrial Average, and the company is ranked No. 48 on the 2025 Fortune 500 list of the largest United States corporations. In 2025, the company was ranked 42th in the Forbes Global 2000. Johnson & Johnson has a global workforce of approximately 138,000 employees who are led by the company's current chairman and chief executive officer, Joaquin Duato. Johnson & Johnson is one of the world's most valuable companies and is one of only two U.S.-based companies that has a prime credit rating of AAA.
- Industry
- Pharmaceuticals
Valuation
Valuation Data UnavailablePrice-based valuation metrics (P/E, P/B) require real-time stock price data which is not included in SEC filings.
Benjamin Graham: Graham recommended P/E ratio not exceed 15 for reasonable valuation. Understanding valuation metrics
Profitability
Above-Average Marginsvs 28.5% sector median / 26.8% avg
Generates $31.7 in profit for every $100 of shareholder equity. Higher than 53% in Health Care.
vs 7.2% sector median / 5.9% avg
Keeps 27 cents of every dollar in revenue as profit. Higher than 84% in Health Care.
4th consecutive year of revenue growth.
* Some quarterly data is missing. Values are calculated based on annual report figures.
Profit margin 362% above sector average.
Warren Buffett: Buffett looks for consistent ROE above 20% as a sign of competitive advantage. How to evaluate profitability
Financial Health
Low Leveragevs 1.31 sector median / 1.98 avg
Carries $0.50 in debt for every $1 of equity. Lower debt than 100% in Health Care. Debt has increased over the past 5 years.
Debt-to-equity ratio of 0.50 is below 0.5.
Peter Lynch: Lynch: normal balance sheet has 75% equity, 25% debt. Understanding financial health
Dividend
Dividend Data UnavailableDividend yield data is not available from SEC filings. Check the company's investor relations page for dividend information.
As of FY2025 · SEC 10-K · Updated Mar 11, 2026
Johnson & Johnson 10-Year Revenue, Profit & Cash Flow History
Annual Financials
FY2025 - FY2016| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $94.2B(+6.0%) | $88.8B(+4.3%) | $85.2B(+6.5%) | $80.0B(+1.6%) | $78.7B(-4.7%) | $82.6B(+0.6%) | $82.1B(+0.6%) | $81.6B(+6.7%) | $76.5B(+6.3%) | $71.9B(+2.6%) |
| Net Income | $26.8B(+90.6%) | $14.1B(-60.0%) | $35.2B(+95.9%) | $17.9B(-14.1%) | $20.9B(+41.9%) | $14.7B(-2.7%) | $15.1B(-1.2%) | $15.3B(+1076.7%) | $1.3B(-92.1%) | $16.5B(+7.3%) |
| Total Assets | $199.2B | $180.1B | $167.6B | $187.4B | $182.0B | $174.9B | $157.7B | $153.0B | $157.3B | $141.2B |
| Total Debt | $41.4B | $32.4B | $27.4B | $28.4B | $32.1B | $34.4B | $26.5B | $27.7B | $30.7B | $22.4B |
| Total Equity | $81.5B | $71.5B | $68.8B | $76.8B | $74.0B | $63.3B | $59.5B | $59.8B | $60.2B | $70.4B |
| Profit Margin | 28.5% | 15.8% | 41.3% | 22.4% | 26.5% | 17.8% | 18.4% | 18.8% | 1.7% | 23.0% |
| ROE | 32.9% | 19.7% | 51.1% | 23.4% | 28.2% | 23.3% | 25.4% | 25.6% | 2.2% | 23.5% |
| ROA | 13.5% | 7.8% | 21.0% | 9.6% | 11.5% | 8.4% | 9.6% | 10.0% | 0.8% | 11.7% |
Quarterly Financials
Last 8 quarters| Metric | Q1 2026 | Q3 2025 | Q2 2025 | Q1 2025 | Q3 2024 | Q2 2024 | Q1 2024 | Q3 2023 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $21.9B | $66.3B | $43.8B | $21.4B | $63.8B | $42.4B | $20.9B | $60.1B |
| Net Income | $11.0B | $10.6B | $7.9B | $3.3B | $31.1B | $5.1B | $-68,000,000 | $14.4B |
| Total Assets | $199.2B | $180.1B | $180.1B | $180.1B | $167.6B | $167.6B | $167.6B | $187.4B |
As of FY2025 · SEC 10-K · Updated Mar 11, 2026
6 insiders sold shares worth $48.2M, despite revenue growth of +6.0% YoY. Divergence signal strength: 40/100.
Insider Trading
Source: SEC EDGAR Form 4 filings. Only purchase (P) and sale (S) transactions shown.
Johnson & Johnson Dividend Safety Analysis & Growth History
Dividend Status
Dividend PayerThis company pays dividends. Historical dividend data shown below.
5-year dividend CAGR: -0.7%.
Annual Dividends
2016 - 2025| Metric | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Dividend/Share | $3.15 | $3.32 | $3.54 | $3.75 | $3.98 | $4.19 | $4.45 | $4.70 | $4.91 | $3.84 |
| YoY Growth | +6.8% | +5.4% | +6.6% | +5.9% | +6.1% | +5.3% | +6.2% | +5.6% | +4.5% | -21.8% |
| Payments | 4 | 4 | 3 | 4 | 4 | 4 | 4 | 4 | 4 | 3 |
| Increased | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | No |
Learn more: Dividend investing guide | How to evaluate dividend safety
As of FY2025 · SEC 10-K · Updated Mar 11, 2026
Johnson & Johnson Free Cash Flow & Dividend Coverage
Generates approximately $54M in free cash flow per day.
Cash Flow History
FY2016 - FY2025| Metric | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating CF | $18.8B | $21.1B | $22.2B | $23.4B | $23.5B | $23.4B | $21.2B | $22.8B | $24.3B | $24.5B |
| CapEx | -$3.2B | -$3.3B | -$3.7B | -$3.5B | -$3.3B | -$3.7B | -$4.0B | -$4.5B | -$4.4B | -$4.8B |
| Free Cash Flow | $15.5B | $17.8B | $18.5B | $19.9B | $20.2B | $19.8B | $17.2B | $18.2B | $19.8B | $19.7B |
| FCF Margin | 21.6% | 23.3% | 22.7% | 24.3% | 24.4% | 25.1% | 21.5% | 21.4% | 22.3% | 20.9% |
Source: SEC EDGAR 10-K filings. FCF = Operating Cash Flow - Capital Expenditures. Free cash flow guide
As of FY2025 · SEC 10-K · Updated Mar 11, 2026
Johnson & Johnson Risk Factors
Company-disclosed SEC risk factors
Risk factors are disclosed by the company in its SEC Form 10-K, Item 1A. Billiver does not classify or summarize company-specific legal, operational, financial, or market risks here.
Sector context: Health Care. This is not a Billiver risk assessment for JNJ.
Source note: the SEC Form 10-K includes Item 1A, "Risk Factors." The full risk-factor text should be read from the company’s own SEC filing.
Johnson & Johnson FAQ
What is Johnson & Johnson's annual revenue?
Johnson & Johnson (JNJ) reported $92.1 billion in trailing twelve-month (TTM) revenue. This financial data is compiled from SEC EDGAR 10-K filings.
Is Johnson & Johnson profitable?
Yes, Johnson & Johnson is profitable with a 27.3% net profit margin and $25.1 billion in net income (TTM). All figures from SEC EDGAR 10-K filings.
Does Johnson & Johnson pay dividends?
Yes, Johnson & Johnson pays regular dividends. View the full dividend history and payout analysis on this page.
What is Johnson & Johnson's financial health score?
Johnson & Johnson has a financial health score of 75/100 (Grade: B), evaluating profitability, solvency, liquidity, and growth based on SEC EDGAR data.
How many years of Johnson & Johnson financial data are available?
10 years of financial data are available for Johnson & Johnson from FY2016 to FY2025. All figures are compiled from SEC EDGAR 10-K filings.